92 related articles for article (PubMed ID: 17317676)
1. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Calvo E; Malik SN; Siu LL; Baillargeon GM; Irish J; Chin SF; Santabarbara P; Kreisberg JI; Rowinsky EK; Hidalgo M
Ann Oncol; 2007 Apr; 18(4):761-7. PubMed ID: 17317676
[TBL] [Abstract][Full Text] [Related]
2. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
3. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Thomas F; Rochaix P; Benlyazid A; Sarini J; Rives M; Lefebvre JL; Allal BC; Courbon F; Chatelut E; Delord JP
Clin Cancer Res; 2007 Dec; 13(23):7086-92. PubMed ID: 18056187
[TBL] [Abstract][Full Text] [Related]
6. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Soulieres D; Senzer NN; Vokes EE; Hidalgo M; Agarwala SS; Siu LL
J Clin Oncol; 2004 Jan; 22(1):77-85. PubMed ID: 14701768
[TBL] [Abstract][Full Text] [Related]
8. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL
Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044
[TBL] [Abstract][Full Text] [Related]
9. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Gross ND; Bauman JE; Gooding WE; Denq W; Thomas SM; Wang L; Chiosea S; Hood BL; Flint MS; Sun M; Conrads TP; Ferris RL; Johnson JT; Kim S; Argiris A; Wirth L; Nikiforova MN; Siegfried JM; Grandis JR
Clin Cancer Res; 2014 Jun; 20(12):3289-98. PubMed ID: 24727329
[TBL] [Abstract][Full Text] [Related]
11. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
12. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
15. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
White-Koning M; Civade E; Geoerger B; Thomas F; Le Deley MC; Hennebelle I; Delord JP; Chatelut E; Vassal G
Clin Cancer Res; 2011 Jul; 17(14):4862-71. PubMed ID: 21653689
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
17. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
